Hard To Treat Diseases (HTDS) Obtains HAS Certificate Apr 15, 2009 10:37:00 AM
SHENZHEN, China, April 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com China based operating subsidiary Mellow Hope has obtained the HAS certificate (Halal Assurance system) issued by the Hangzhou Muslim Association. The HAS covers Group ACYW135 and A+C Meningococcal Polysaccharide Vaccine and Flu vaccine. Mr. Terry Yuan CEO said "With this certificate, we can export all our products to all the Muslim countries. Last year, we had successfully bid the tender of 75,000 vials of Group ACYW135 Meningococcal Polysaccharide Vaccine in Indonesia, and the tender for 300,000 vials of the same application is in the process. We are hopeful that our successful tender experience of last year, will assist Mellow Hope to win the tender again this year."
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo*htdsmedical.com; For any corporate matters, please contact corporate*htdsmedical.com, www.htdsmedical.com
SOURCE Hard to Treat Diseases
---------------------------------------------- For medical and scientific dialogue inquiry only please contact medicalinfo*htdsmedical.com; For any corporate matters please contact corporate*htdsmedical.com www.htdsmedical.com Posted by Average Joe on :
Closed at .0005 today. Could move in the morning .... imho
Posted by gumzsa on :
HTDS .0007 up 133% today with a strong close. Could have some steam at mondays open.
Posted by Average Joe on :
At .0016 ....up 129%!! Had a feeling that move late Friday could carry over.
Posted by Average Joe on :
Hit .0018 .... up 157% !!
Posted by Average Joe on :
Volume is huge, over 500 million.
Posted by Average Joe on :
I feel like that old song on this stock .... " Alone Again, Naturally ".
Posted by Average Joe on :
Hard to Treat Diseases, Inc. (HTDS) Finalizes Agreement with Yunnan Walvax Biotech Jun 15, 2009 12:09:00 PM
BEIJING, China, June 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com is pleased to announce that its Mellow Hope Bio Chem China division has signed an agreement with Yunnan Walvax Biotech Co., Ltd on the issue of Haemophilus influenza type "B" conjugate vaccine.
Under the terms of the agreement Mellow Hope will be fully authorized to do the International marketing of Haemophilus influenza type "B" conjugate vaccine in the global market.
HTDS intends to begin the registration process in Chile, India, Indonesia, Egypt, and Russia, commencing in June 2009 with the brand name "MEVAC-Hib".
Yunnan Walvax Biotech Co., Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Note this CTV web link is an unauthorized link, provided for the convenience of the reader.
CONTACT: corporate*htdsmedical.com
SOURCE Hard to Treat Diseases
Posted by Average Joe on :
Dipped down to .0012, now back to .0018 on big volume.
Posted by Average Joe on :
At .0019 .... up 171% !!
Posted by Average Joe on :
At .0024 .... up 243% on 750 million shares. Huge move off that news and Friday's late surge. But again, all by myself ??
Posted by NunyaBidness on :
I'm just learning and can't use real money yet. On my practice trading account I am with you.
Posted by Danzo Big Dreams on :
Based on what I've looked at, I think HTDS will be a QUICK multi-bagger. I plan to buy about 6.3 million shares tomorrow.
Posted by gumzsa on :
I played it just got out way too early dang it. Got in at .0003 last friday.
Posted by Average Joe on :
Hit .0029 .... up 53% from yesterday's close. Currently at .0024 on BIG volume !!
Posted by Danzo Big Dreams on :
"I played it just got out way too early dang it."
Yeah, I did that with CDIV. The share price of CDIV now is about 89 TIMES what I sold it for.